Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer.
Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.
Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.
Location: United States, North Carolina, Durham
Employees: 11-50
Founded date: 2015
Investors 6
| Date | Name | Website |
| 20.10.2022 | Checkmate ... | checkmatec... |
| 17.05.2025 | Cowtown An... | cowtownang... |
| 10.03.2022 | RTP Capita... | rtpcapital... |
| - | NOLA Angel... | nolaangeln... |
| - | K2X | k2x.capita... |
| - | Johnson Ve... | jvpfund.co... |
Mentions in press and media 4
| Date | Title | Description |
| 18.08.2025 | Hatteras Venture Partners: Over $200 Million Raised For Two Healthcare Funds | Hatteras Venture Partners has announced the final closings of Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I, LP (HOF I), securing over $200 million in capital commitments from limited partners. This milestone coinc... |
| 14.11.2024 | CN Bio launches PhysioMimix Bioavailability assay kit: Human 18 | Unique solution enabling researchers to profile human oral drug bioavailability in vitro, in their own laboratories Expands access to CN Bio’s robust multi-organ Gut/Liver-on-a-chip model to accelerate and de-risk clinical progression of dr... |
| 11.08.2020 | Altis Biosystems Completes $3.1M Seed Round | CHAPEL HILL, N.C., Altis Biosystems ("Altis") today announced completion of a seed series investment that was oversubscribed by nearly 50%, raising $3.1 million. >> Click here for more funding data on Altis Biosystems &g... |
| 11.08.2020 | Altis Biosystems Raises $3.1M Seed Round | Altis Biosystems today announced completion of a seed series investment that was oversubscribed by nearly 50%, raising $3.1 million. Altis was formed as a spin-out of the UNC-Chapel Hill Biomedical Engineering Department and developed a tec... |